Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment

Annals of Hematology

Volumn 89, Issue 7, 2010, Pages 681-689

  Moon, Joon Ho ^a   Kim, Shi Nae ^a   Kang, Byung Woog ^a   Chae, Yee Soo ^a   Kim, Jong Gwang ^a   Baek, Jin Ho ^b   Park, Jae Hoo ^b   Song, Moo Kon ^c   Chung, Joo Seop ^c   Won, Jong Ho ^d   Lee, Sang Min ^e   Joo, Young Don ^e   Kim, Yeo Kyeoung ^f   Kim, Hyeong Joon ^f   Jo, Deog Yeon ^g   Sohn, Sang Kyun ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d Soonchunhyang University College of Medicine   (South Korea)

^e Inje University College of Medicine   (South Korea)

^f Chonnam National University   (South Korea)

^g Chungnam National University College of Medicine   (South Korea)

Author keywords

Azacitidine; International Prognostic Scoring System; Lactate dehydrogenase; Myelodysplastic syndrome; WHO Prognostic Scoring System

Indexed keywords

AZACITIDINE; LACTATE DEHYDROGENASE; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; SURVIVAL; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RISK FACTOR; SURVIVAL RATE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RISK FACTORS; SURVIVAL RATE;

EID: 77953079923     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0921-5     Document Type: Article

References (15)

1. Sloand EM (2008) Myelodysplastic syndromes: Introduction. Semin Hematol 45:1-2
2. Valent P, Horny HP, Bennett JM et al (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 31:727-736
3. Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088
4. Alessandrino EP, Della Porta MG, Bacigalupo A et al (2008) WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: A study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 112:895-902
5. Malcovati L, Germing U, Kuendgen A et al (2007) Timedependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510
6. Silverman LR, Demakos EP, Peterson BL et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440
7. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 10:223-232
8. Kantarjian H, Issa JP, Rosenfeld CS et al (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106:1794-1803
9. Kantarjian HM, O'Brien S, Shan J et al (2007) Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109:265-273
10. Kantarjian HM, O'Brien S, Huang X et al (2007) Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: Comparison with historical experience. Cancer 109:1133-1137
11. Cheson BD, Greenberg PL, Bennett JM et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425
12. Cheson BD, Bennett JM, Kantarjian H et al (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674
13. Park MJ, Kim HJ, Kim SH et al (2008) Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Eur J Haematol 81:364-373
14. Najfeld V, Chen A, Scalise A et al (1994) Myelodysplastic syndrome transforming to acute promyelocytic-like leukemia with trisomy and rearrangement of chromosome 11. Genes Chromosomes Cancer 10:15-25
15. Lubbert M, Wijermans P, Kunzmann R et al (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following lowdose treatment with the DNA methylation inhibitor 5-aza-2'- deoxycytidine. Br J Haematol 114:349-357